微结合亲和性血液过滤器在实体转移性肿瘤中首次用于人体时对循环肿瘤细胞的快速清除。
First-In-Human Rapid Removal of Circulating Tumor Cells in Solid Metastatic Neoplasia by Microbind Affinity Blood Filter.
作者信息
Ilic Sanja, Premuzic Vedran
机构信息
ExThera Medical Corporation, Martinez, California, USA.
Mira Costa College, Oceanside, California, USA.
出版信息
Blood Purif. 2025;54(2):138-140. doi: 10.1159/000542325. Epub 2024 Nov 4.
INTRODUCTION
We conducted a first-in-human trial evaluating safety and the potential for combined pathogen and circulating tumor cell (CTC) removal in patients with solid metastatic cancers.
METHODS
The Seraph procedure was performed at a hemodialysis clinic on 10 consecutive patients with metastatic cancer whose liquid biopsy was positive for the epithelial cell adhesion molecule. All the patients exerted positive bacterial or fungal isolates.
RESULTS
We have demonstrated the ability of Seraph100® Filter to remove both pathogens and CTCs, with median reduction of 71% within 120 min, from patient blood.
CONCLUSION
High-yield CTC clearance could potentially benefit patients in diagnostic and personalized treatment of cancer to be elucidated in further research.
引言
我们开展了一项首次人体试验，评估实体转移性癌症患者中联合清除病原体和循环肿瘤细胞（CTC）的安全性及可能性。
方法
在一家血液透析诊所，对10例连续的转移性癌症患者进行了Seraph程序，这些患者的液体活检上皮细胞粘附分子呈阳性。所有患者均检出阳性细菌或真菌分离株。
结果
我们已证明Seraph100®过滤器能够从患者血液中清除病原体和CTC，在120分钟内中位数减少71%。
结论
高产量的CTC清除在癌症的诊断和个性化治疗中可能使患者受益，有待进一步研究阐明。
Zotero 插件